SCHEDULE 13G/A: Blue Owl Capital Holdings LP Amends AEON Biopharma Stake, Reports 3.81% Beneficial Ownership

Blue Owl Capital Holdings LP has filed an amendment to its Schedule 13G, disclosing a 3.81% beneficial ownership stake in AEON Biopharma, Inc. as of December 31, 2024.

Summary

• Blue Owl Capital Holdings LP filed an Amendment No. 1 to its Schedule 13G regarding its beneficial ownership in AEON Biopharma, Inc.
• As of December 31, 2024, Blue Owl Capital Holdings LP beneficially owned 3,049,361 shares of AEON Biopharma, Inc.'s Class A common stock.
• This ownership represents 3.81% of the Class A common stock outstanding.
• The percentage is calculated based on 79,970,693 shares of Class A common stock outstanding as of January 7, 2025, as reported in AEON Biopharma's Schedule 14A filed on January 23, 2025.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is inherently neutral. The implied reduction in stake (from an amendment to below 5%) could be seen as a slight negative, but the filing itself contains no positive or negative operational or financial news.

Positives

• The filing indicates that Blue Owl Capital Holdings LP holds a significant, albeit non-controlling, stake in AEON Biopharma, Inc., suggesting continued investment interest.
• The certification confirms the investment is for ordinary course business purposes, not for control, which can be viewed positively by management.

Negatives

• The filing is an amendment reporting a beneficial ownership stake of 3.81%, which is below the 5% threshold typically associated with initial Schedule 13G filings, potentially indicating a reduction in Blue Owl Capital Holdings LP's stake in AEON Biopharma, Inc. from a previous higher position.

Risks

• A potential reduction in a significant institutional investor's stake, as implied by the amendment reporting a position below 5%, could be perceived negatively by the market, potentially signaling a lack of confidence or a shift in investment strategy by Blue Owl Capital Holdings LP.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of institutional ownership in the biopharma sector. While it doesn't provide specific industry trends, the continued, albeit reduced, stake by a significant investment firm like Blue Owl Capital Holdings LP in a biopharma company like AEON Biopharma indicates ongoing institutional interest in the sector, even if individual positions are adjusted.

Stakeholder Impact

• Shareholders: May interpret the reduction in stake by Blue Owl Capital Holdings LP as a signal of reduced confidence, potentially leading to selling pressure.
• Company Management: May need to understand the reasons behind the reduction in stake by a significant investor.

Key Dates

Keywords

AEON Biopharma, Blue Owl Capital Holdings, Schedule 13G, beneficial ownership, Class A common stock, institutional investment, SEC filing, equity stake, biopharma